Bruker Corporation (BRKR) is a publicly traded Healthcare sector company. As of May 20, 2026, BRKR trades at $44.76 with a market cap of $6.51B and a P/E ratio of -182.83. BRKR moved +3.87% today. Year to date, BRKR is -13.64%; over the trailing twelve months it is +15.89%. Its 52-week range spans $28.53 to $72.94. Analyst consensus is buy with an average price target of $47.00. Rallies surfaces BRKR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bruker jumps as Q1 revenue and adjusted EPS beat estimates, FY26 outlook reaffirmed: Bruker shares surged after reporting Q1 2026 results that beat Wall Street expectations on both revenue and adjusted EPS. The company posted $823.4 million in revenue (+2.7% YoY) and adjusted EPS of $0.31 versus $0.23 expected while reaffirming full-year guidance.
| Metric | Value |
|---|---|
| Price | $44.76 |
| Market Cap | $6.51B |
| P/E Ratio | -182.83 |
| EPS | $-0.24 |
| Dividend Yield | 0.05% |
| 52-Week High | $72.94 |
| 52-Week Low | $28.53 |
| Volume | 1.62M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.46B |
| Net Income | $-9.40M |
| Gross Margin | 45.29% |
7 analysts cover BRKR: 0 strong buy, 3 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $47.00.